Isis Pharmaceuticals, Inc. has earned a $1.5 million milestone payment from GSK related to the advancement of the ISIS-GSK4Rx program to treat an undisclosed ocular disease.   “Our collaboration with GSK has been very productive resulting in four drugs in development,” said B. Lynne Parshall, chief operating officer at Isis. “We look forward to advancing ISIS-GSK4Rx into clinical development and providing more information on the target and disease opportunity, which we are very...